Poxel Announces its Participation at Upcoming Investor Conferences
2023年10月12日 - 2:30PM
ビジネスワイヤ(英語)
Regulatory News:
POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage
biopharmaceutical company developing innovative treatments for
chronic serious diseases with metabolic pathophysiology, including
non-alcoholic steatohepatitis (NASH) and rare metabolic disorders,
today announced that it will participate at two upcoming investor
conferences.
- 7th Annual H.C.Wainwright NASH Investor Conference – virtual
conference Date: October 24, 2023 Thomas Kuhn, Chief Executive
Officer, and Pascale Fouqueray, Executive Vice President, Clinical
Development and Regulatory Affairs, will present the NASH related
programs of Poxel during a dedicated virtual presentation, and will
be available to investors for one-on-one virtual meetings.
- Healthtech Innovation Days – Paris, France – in-person and
virtual conference Date: October 24-25, 2023 Thomas Kuhn, Chief
Executive Officer, and other members of the management of Poxel,
will be available to investors for one-on-one in person and virtual
meetings.
About NASH
Non-alcoholic steatohepatitis (NASH) is a metabolic disease with
no clear disease origin that is quickly becoming a worldwide
epidemic. It is characterized by the accumulation of fat in the
liver causing inflammation and fibrosis. The disease can be silent
for a long period of time, but once it accelerates, severe damage
and liver cirrhosis can occur, which can significantly impact liver
function or can even result in liver failure or liver cancer.
Typical risk factors for NASH include obesity, elevated levels of
blood lipids (such as cholesterol and triglycerides) and type 2
diabetes. Currently no curative or specific therapies are
available.
About Poxel SA
Poxel is a clinical stage biopharmaceutical company
developing innovative treatments for chronic serious diseases
with metabolic pathophysiology, including non-alcoholic
steatohepatitis (NASH) and rare disorders. For the treatment of
NASH, PXL065 (deuterium-stabilized R-pioglitazone) met its
primary endpoint in a streamlined Phase 2 trial (DESTINY-1). In
rare diseases, development of PXL770, a first-in-class
direct adenosine monophosphate-activated protein kinase (AMPK)
activator, is focused on the treatment of adrenoleukodystrophy
(ALD) and autosomal dominant polycystic kidney disease (ADPKD).
TWYMEEG® (Imeglimin), Poxel’s first-in-class product that
targets mitochondrial dysfunction, is marketed for the treatment of
type 2 diabetes in Japan by Sumitomo Pharma and Poxel expects to
receive royalties and sales-based payments. Poxel has a strategic
partnership with Sumitomo Pharma for Imeglimin in Japan, China, and
eleven other Asian countries. Listed on Euronext Paris, Poxel is
headquartered in Lyon, France, and has subsidiaries in Boston, MA,
and Tokyo, Japan.
For more information, please visit: www.poxelpharma.com
All statements other than statements of historical fact included
in this press release about future events are subject to (i) change
without notice and (ii) factors beyond the Company’s control. These
statements may include, without limitation, any statements preceded
by, followed by or including words such as “target,” “believe,”
“expect,” “aim,” “intend,” “may,” “anticipate,” “estimate,” “plan,”
“project,” “will,” “can have,” “likely,” “should,” “would,” “could”
and other words and terms of similar meaning or the negative
thereof. Forward-looking statements are subject to inherent risks
and uncertainties beyond the Company’s control that could cause the
Company’s actual results or performance to be materially different
from the expected results or performance expressed or implied by
such forward-looking statements. The Company does not endorse or is
not otherwise responsible for the content of external hyperlinks
referred to in this press release.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231011367166/en/
Investor relations / Media
Aurélie Bozza Investor Relations & Corporate Communications
Vice-president aurelie.bozza@poxelpharma.com +33 6 99 81 08 36
NewCap Nicolas Fossiez, Aurélie Manavarere / Arthur Rouillé
poxel@newcap.eu +33 1 44 71 94 94
Poxel (EU:POXEL)
過去 株価チャート
から 5 2024 まで 6 2024
Poxel (EU:POXEL)
過去 株価チャート
から 6 2023 まで 6 2024